886例儿童慢性免疫性血小板减少症患者中诊断年龄、性别及免疫病理表现的影响
该研究基于法国全国前瞻性队列OBS'CEREVANCE,纳入886例儿童慢性免疫性血小板减少症(cITP)患者,中位随访5.3年,采用多因素分析探讨诊断年龄、性别及免疫病理表现(IMs)对结局的影响。研究发现以10岁为界将患者分为儿童组(<10岁)与青少年组(≥10岁),青少年组发生≥3级出血、二线治疗、临床和生物学IMs及系统性红斑狼疮(SLE)诊断的风险是儿童组的2至4倍。女性性别和生物学IMs分别与生物学IMs和SLE诊断、二线治疗及SLE诊断的更高风险独立相关。
要点
- 诊断年龄≥10岁的青少年cITP患者发生≥3级出血、二线治疗、IMs及SLE的风险是<10岁儿童的2至4倍。
- 女性性别与生物学IMs风险独立相关,生物学IMs与SLE诊断风险独立相关。
- 诊断年龄、性别和生物学IMs组合可定义各结局特异性风险组,有助于临床管理。
核心结论
- 诊断年龄、性别和生物学IMs影响儿童cITP的长期结局,据此定义的风险组有助于临床管理和进一步研究。
研究设计与样本
- 法国全国前瞻性队列OBS'CEREVANCE,纳入886例儿童cITP患者,中位(最小-最大)随访5.3(1.0-29.3)年,采用多因素分析。
主要发现
- 以10岁为界定义两组:ITP诊断<10岁(儿童)和≥10岁(青少年)。
- 青少年组发生≥3级出血、二线治疗、临床和生物学IMs及SLE诊断的风险是儿童组的2至4倍。
- 女性性别与生物学IMs风险独立相关,生物学IMs与SLE诊断风险独立相关。
- 女性性别与二线治疗风险独立相关。
- 患者可聚类为轻度与重度表型,分别更常见于儿童和青少年。
临床怎么用
- 作者指出,所定义的风险组将有助于临床管理和进一步研究。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Pediatric chronic immune thrombocytopenia (cITP) is a heterogeneous condition in terms of bleeding severity, second-line treatment use, association with clinical and/or biological immunopathological manifestations (IMs), and progression to systemic lupus erythematosus (SLE). No risk factors for these outcomes are known. Specifically, whether age at ITP diagnosis, sex, or IMs impact cITP outcomes is unknown. We report the outcomes of patients with pediatric cITP from the French nationwide prospective cohort OBS'CEREVANCE. We used multivariate analyses to investigate the effect of age at ITP diagnosis, sex, and IMs on cITP outcomes. We included 886 patients with a median (min-max) follow-up duration of 5.3 (1.0-29.3) years. We identified an age cutoff that dichotomized the risk of the outcomes and defined two risk groups: patients with ITP diagnosed <10 years (children) and ≥ 10 years (adolescents). Adolescents had a two to four-fold higher risk of grade ≥3 bleeding, second-line treatment use, clinical and biological IMs, and SLE diagnosis. Moreover, female sex and biological IMs were independently associated with higher risks of biological IMs and SLE diagnosis, second-line treatment use, and SLE diagnosis, respectively. The combination of these three risk factors defined outcome-specific risk groups. Finally, we showed that patients clustered in mild and severe phenotypes, more frequent in children and adolescents, respectively. In conclusion, we identified that age at ITP diagnosis, sex, and biological IMs impacted the long-term outcomes of pediatric cITP. We defined risk groups for each outcome, which will help clinical management and further studies.
引用
- Pincez T, Fernandes H, Pasquet M, et al. Impact of age at diagnosis, sex, and immunopathological manifestations in 886 patients with pediatric chronic immune thrombocytopenia. Am J Hematol. 2023. PMID: 36882195. doi:10.1002/ajh.26900
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。